Response to Inhaled Nitric Oxide and Clinical Outcome in Very Low Birth Weight Infants with Early Pulmonary Hypertension

J. Cho, B. Lee, M. Oh, Teahyen Cha, Jiyoon Jeong, Euiseok Jung, A. Kim, Ki-Soo Kim
{"title":"Response to Inhaled Nitric Oxide and Clinical Outcome in Very Low Birth Weight Infants with Early Pulmonary Hypertension","authors":"J. Cho, B. Lee, M. Oh, Teahyen Cha, Jiyoon Jeong, Euiseok Jung, A. Kim, Ki-Soo Kim","doi":"10.5385/nm.2020.27.3.133","DOIUrl":null,"url":null,"abstract":"Purpose: To determine the efficacy of inhaled nitric oxide (iNO) in very low birth weight (VLBW) infants with early pulmonary hypertension (PH). Methods: We reviewed the medical records of 22 preterm infants who were born <30 weeks of gestational age with birth weight <1,500 g, diagnosed with early PH, and treated with iNO within the first 72 hours after birth. Responders were defined by a reduction in FiO2 >20% and/or oxygenation index (OI) >20% from the baseline values at 1 hour after beginning iNO therapy. Cardiorespiratory support indices including OI, oxygen saturation index, and vasoactive-inotropic score (VIS) were serially obtained for 96 hours following iNO therapy. Results: The mean gestational age of the patients was 26.1±2.0 weeks and the mean birth weight was 842±298 g. The mean OI at the start of iNO was 63.8±61.0. Improvement in oxygenation indicated by prompt decrease in FiO2 and OI from the baseline values were observed 1 hour after beginning iNO therapy and lasted up to 96 hours. After iNO therapy, VIS increased until 24 hours and decreased thereafter. At 1 hour after iNO, 16 patients (73%) were classified as responders and six (27%) as nonresponders. Compared with nonresponders, responders did not demonstrate the beneficial effect of iNO in terms of short-term survival and neonatal complications. The 1-year mortality rate did not differ between responders (56%) and nonresponders (67%). Conclusion: Although iNO treatment immediately improved oxygenation in most VLBW infants with early severe PH, the long-term mortality rate was high. A largescale study is needed to determine whether the initial response to iNO can predict patients’ survival.","PeriodicalId":32945,"journal":{"name":"Neonatal Medicine","volume":"27 1","pages":"133-140"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neonatal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5385/nm.2020.27.3.133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: To determine the efficacy of inhaled nitric oxide (iNO) in very low birth weight (VLBW) infants with early pulmonary hypertension (PH). Methods: We reviewed the medical records of 22 preterm infants who were born <30 weeks of gestational age with birth weight <1,500 g, diagnosed with early PH, and treated with iNO within the first 72 hours after birth. Responders were defined by a reduction in FiO2 >20% and/or oxygenation index (OI) >20% from the baseline values at 1 hour after beginning iNO therapy. Cardiorespiratory support indices including OI, oxygen saturation index, and vasoactive-inotropic score (VIS) were serially obtained for 96 hours following iNO therapy. Results: The mean gestational age of the patients was 26.1±2.0 weeks and the mean birth weight was 842±298 g. The mean OI at the start of iNO was 63.8±61.0. Improvement in oxygenation indicated by prompt decrease in FiO2 and OI from the baseline values were observed 1 hour after beginning iNO therapy and lasted up to 96 hours. After iNO therapy, VIS increased until 24 hours and decreased thereafter. At 1 hour after iNO, 16 patients (73%) were classified as responders and six (27%) as nonresponders. Compared with nonresponders, responders did not demonstrate the beneficial effect of iNO in terms of short-term survival and neonatal complications. The 1-year mortality rate did not differ between responders (56%) and nonresponders (67%). Conclusion: Although iNO treatment immediately improved oxygenation in most VLBW infants with early severe PH, the long-term mortality rate was high. A largescale study is needed to determine whether the initial response to iNO can predict patients’ survival.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
极低出生体重儿早期肺动脉高压对吸入一氧化氮的反应和临床结局
目的:确定吸入一氧化氮(iNO)治疗极低出生体重(VLBW)婴儿早期肺动脉高压(PH)的疗效。方法:我们回顾了22名早产儿的医疗记录,这些早产儿在开始iNO治疗后1小时出生时的氧合指数(OI)比基线值高出20%和/或>20%。iNO治疗后96小时连续获得心肺支持指数,包括OI、血氧饱和度指数和血管活性肌力评分(VIS)。结果:患者的平均胎龄为26.1±2.0周,平均出生体重为842±298g。iNO开始时的平均OI为63.8±61.0。iNO治疗开始1小时后观察到FiO2和OI从基线值迅速下降所表明的氧合改善,并持续了96小时。iNO治疗后,VIS增加至24小时,此后下降。iNO后1小时,16名患者(73%)被归类为有反应者,6名患者(27%)被分类为无反应者。与无反应者相比,有反应者没有证明iNO在短期生存率和新生儿并发症方面的有益作用。有应答者(56%)和无应答者(67%)的1年死亡率没有差异。结论:尽管iNO治疗立即改善了大多数早期重度PH的极低出生体重儿的氧合,但长期死亡率很高。需要进行大规模的研究来确定对iNO的初始反应是否可以预测患者的生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
17
审稿时长
12 weeks
期刊最新文献
Full-Term Baby with Cerebellar Hemorrhage Referred for Severe Jaundice Occurring within the First 3 Days of Life Should We Consider UGT1A1 Mutation Analysis in Evaluating the Prolonged Jaundice of Newborn Infants? A Case of Oropharyngeal Teratoma Associated with Subluxation of Temporomandibular Joint: A Case Report Does Neonatal Microbiome Research Encompass the Placental Transfer Pathway? Beta Thalassemia Presenting with Neonatal Cholestasis and Extensive Hemosiderosis: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1